Connect Biopharma Holdings Ltd., a clinical-stage biopharmaceutical company, has announced the initiation of its Phase 2 Seabreeze STAT Asthma study to evaluate the safety and efficacy of rademikibart for treating acute exacerbations in asthma. This study, which is expected to report topline data in the first half of 2026, aims to establish rademikibart as a potentially groundbreaking biologic treatment for patients experiencing acute asthma exacerbations. Following positive results from a previous global Phase 2 trial, rademikibart has demonstrated the ability to rapidly improve lung function within 24 hours and provide sustained improvements over 24 weeks. The company is also set to begin a similarly-designed Phase 2 study for COPD patients.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。